



European Medicines Agency

Doc. Ref. EMEA/24175/2009  
P/16/2009

**EUROPEAN MEDICINES AGENCY DECISION**

**of 27 January 2009**

**on the granting of a product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida HCT), (EMEA-000399-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended**

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

## EUROPEAN MEDICINES AGENCY DECISION

of 27 January 2009

**on the granting of a product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida HCT), (EMEA-000399-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended**

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Novartis Europharm Ltd. on 12 September 2008 under Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 December 2008 in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended.

WHEREAS:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a Decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1

<sup>2</sup> OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

*Article 1*

A waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida HCT), film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

*Article 2*

This decision is addressed to Novartis Europharm Ltd., Wimblehurst Road, Horsham, RH 12 5AB, United Kingdom.

Done at London, 27 January 2009

For the European Medicines Agency  
Thomas Lönngren  
Executive Director

(Signature on file)



European Medicines Agency  
*Pre-authorisation Evaluation of Medicines for Human Use*

Doc. Ref. EMEA/PDCO/674513/2008  
EMEA-000399-PIP01-08

## **OPINION OF THE PAEDIATRIC COMMITTEE ON THE GRANTING OF A PRODUCT-SPECIFIC WAIVER**

### **Scope of the application**

Active substance:

Amlodipine besylate, valsartan, hydrochlorothiazide

Invented name:

Imprida HCT

Condition(s):

Essential hypertension

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Ltd.

### **Basis for opinion**

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd. submitted to the EMA on 12 September 2008 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 16 October 2008.

## **Opinion**

The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report, to grant a product-specific waiver for all subsets of the paediatric population and all the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its appendix.

London, 12 December 2008

On behalf of the Paediatric Committee  
Dr Daniel Brasseur, Chairman

(Signature on file)